Leadership

Xytogen Biotech’s Factorfive stem cell-based skin care delivers benefits that are greater than the company claims, says founder and CEO John Aylworth. Available mostly through clinicians’ offices, the formulas are based on a proprietary process that triggers stem cells to send out growth factor signals, which are captured in a ‘conditioned media’ and used as the basis for products.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Medtech Insight talked with GE HealthCare’s chief AI officer Parminder “Parry” Bhatia at HLTH about the firm’s new CareIntellect for Oncology offering to help clinicians make efficient use of multimodal patient data, his vision for projects within AI Innovation Lab, and the future of AI in health care.

Recent moves in the industry include changes at the top at Fennec Pharmaceuticals, plus Opthea Acquires Chief Financial Officer From Amarin, and Disc Medicine gets a new chief technical officer.

In the wake of its recent acquisition of dermatology assets from Canute Pharma, UK-based Aspire Pharma is looking to new frontiers of expansion in Europe and beyond. Chief executive Richard Condon talks to Generics Bulletin about the next steps on the niche generics and value added medicines firm’s journey.

Our latest roundup of off-patent industry appointments sees Lupin appointing a new president of global specialty, at the same times as several other organizations welcome fresh leadership.

Since taking on the CEO role at Theratechnologies in 2020, Paul Lévesque has made it his priority to beef up the company’s commercial portfolio and look for partnerships on potentially high-value programs. Now, the Canadian biotech is turning a profit for the first time in many years.

Recent moves in the industry include changes at the top at Defence Therapeutics, Trevena and Neurocrine Biosciences, plus Alpha Cognition gets a new chief Financial officer.

The US major is investing over $360m in new money into the UK but the country has being losing its lustre as an appealing place to invest since Brexit and needs to offer more to multinationals.

Fusion Pharmaceuticals Inc CEO John Valliant talked to In Vivo about Canadian leadership in radiopharmaceutical innovation, its differentiated approach, and excitement around combination therapies for precision cancer treatments.